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monest adverse drug reaction (ADR), it is the single most
frequent ADR causing a drug to be withdrawn from the
market. It also prompts the preclinical termination of many
developing drugs, and limits the use of some drugs after
marketing. DILI accounts for more than half of acute liver
failure in the USA, and is the leading cause of nonviral acute
liver injury in the world. The number of cases of DILI is
expected to grow, because of the impacts of progressive
new drugs on the market and the burden of global aging.
Most cases of DILI are mild and self-limiting, after
discontinuation of the culprit agent. However, severe DILI
may be fatal or with permanent sequelae. Early detection
and prevention of severe forms of DILI has been a challenge
for physicians, pharmacists, pharmaceutical industries, and
healthcare administrations globally. This effort commenced
23 years ago when the Russul Uclaf Causality Assessment
Method (RUCAM) was designed to be the scoring system for
the diagnosis of DILI in the Paris international consensus
meeting in 1989. Since then many European countries have
begun to survey self-reported DILI cases nationwide. The
US Food and Drug Administration (FDA) has hosted an
annual DILI conference since 2000. Thereafter, in 2003, the
Drug-Induced Liver Injury Network (DILIN) was established
in the USA with the support of National Diabetes and
Digestive and Kidney Diseases (NIDDK) to collect the data* Division of Gastroenterology, Department of Medicine, Taipei
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doi:10.1016/j.jfma.2011.11.034and bio-specimens of patients with severe DILI from 13
medical centers across the mainland.
The first report of 300 enrolled cases from DILIN dis-
closed that antimicrobial drugs are the leading cause of DILI
in the USA (45.5%), followed by central nervous system
agents (15%).1 Fourteen percent of patients had developed
chronic liver injury, and 8% had died.
Recently, the international Drug-Induced Liver Injury
Consortium (iDILIC), set up by the European non-profit
international Severe Adverse Events Consortium (iSAEC),
has collected bio-specimens and data for DILI globally
(mainly from Europe) and published a first multinational
genome-wide association study (GWAS) of human leukocyte
antigen (HLA) and amoxicillineclavulanate-induced hepa-
totoxicity.2 They found some class I and II HLA genotypes
may affect the susceptibility and severity of this most
prevalent form of DILI in Europe and USA. The other
remarkable finding is the GWAS of flucloxacillin-induced
hepatotoxicity and HLA from the UK. They revealed
patients with HLA-B*5701 have significantly higher risk
of having flucloxacillin-induced liver injury (odds
ratioZ 80.6).3 This highlights the value of genetic studies
in understanding the mechanism of DILI and posits
a successful model for further clinical application.
In Taiwan, only a few single-center studies about DILI
have been reported.4e10 A national database of DILI was not
established until 2011 when the Drug-Induced Liver Injury
Network in Taiwan (DILINT) was launched, sponsored by the
Taiwan Food and Drug Administration (Fig. 1). This is
a multi-center collaborative program to collect the clinical
data of DILI prospectively and retrospectively from six& Formosan Medical Association. All rights reserved.
Figure 1 Schematic flow of the data collection of DILI used by the Drug-Induced Liver Injury Network in Taiwan. a The Taiwan
Drug Relief Foundation is a nonprofit organization authorized by the Taiwan Food and Drug Administration to manage the
compensation system of severe adverse drug reaction. DILIZ drug-induced liver injury.
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showed that antituberculosis drugs are the leading
discriminated agents (27.8%), followed by herbs (20.5%),
and antibiotics (10.0%) (unpublished data). The finding that
antituberculosis drugs and herbs play major roles in DILI in
Taiwan is consistent with findings in mainland China, Hong
Kong, Singapore, Korea and many other countries. This
spotlights the urgent need for a pharmacovigilance program
covering both conventional, Western drugs and herbs.
Global endeavors in the early detection and prevention
of DILI have been developed over the past decade, based on
the gradually growing database. In addition to the above-
mentioned association study of HLA, assaying functional
genetic polymorphisms of the target drug-metabolizing
enzymes is another way to detect the susceptibility
genetic factors of DILI. Since antituberculosis drugs are the
leading culprits for DILI in Taiwan and many Asian coun-
tries, we have recently performed a series of pharmaco-
genetic association studies in this field. We found that
patients with N-acetyltransferase 2 (NAT2) slow acetylator
status, cytochrome P450 2E1(CYP2E1) wild c1/c1 genotype,
glutathione S-transferase M1(GSTM1) null genotype, and
manganese superoxide dismutase (MnSOD, SOD2) mutant C
allele may be at higher risk of antituberculosis DILI.4e7
Patients with all of these risk genotypes may have more
than a 10-fold higher risk of antituberculosis DILI than those
without these genotypes. Although these associations need
to be verified in other ethnic populations with a larger
sample size, this kind of pharmacogenetic or pharmacoge-
nomic approach reveals the potential of early detection
and prevention of DILI caused by some drugs.
A good pharmacovigilance system, which includes
detection of severe DILI, is the hallmark of high-quality
healthcare. By combining the experience and insight of the
various DILI networks and organizations, we could achieve
an extraordinary opportunity to combat DILI. International
collaboration to collect and share database and bio-
specimen repository is just on the way. Further effort is
needed to initiate some large-scale international studies
for detecting biomarkers of severe DILI. Throughinternational efforts and progress in pharmacogenetics and
pharmacogenomics, we then can mitigate DILI and guar-
antee drug safety further.
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